Prognostic factors in breast cancer: one fits all?

Mook, S.

Publication date
2011

Chapter 12

Nederlandse samenvatting

List of publications

Dankwoord

Curriculum vitae



Mook S, Van 't Veer LJ, Rutgers EJ, Ravdin PM, Van de Velde AO, Van Leeuwen FE, Visser O, Schmidt MK. Independent prognostic value of screen detection in invasive breast cancer. *JNCI, accepted for publication.*

Knauer M, **Mook S**, Rutgers EJ, Bender RA, Hauptmann M, Van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, Van 't Veer LJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. *Breast Cancer Res Treat* 2010; 120: 655-661.

Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van 't Veer LJ, Rutgers EJ. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. *Ann Surg Oncol* 2010; 17: 1406-1413.

Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, Van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, Van 't Veer LJ. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. *Ann Oncol* 2010; 21: 717-722.

Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, Armstrong N, Van 't Veer LJ, Ravdin PM. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. *Lancet Oncol* 2009; 10: 1070-1076.

Bedard PL, **Mook S**, Piccart-Gebhart MJ, Rutgers ET, Van 't Veer LJ, Cardoso F. MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. *Expert Opinion on Medical Diagnostics* 2009; 3: 193-205.

Mook S, Bonnefoi H, Pruneri G, Larsimont D, Jaskiewicz J, Sabadell MD, MacGrogan G, Van 't Veer LJ, Cardoso F, Rutgers EJ. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. *Eur J Cancer* 2009; 45: 1201-1208.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van 't Veer LJ. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. *Breast Cancer Res Treat* 2009; 116: 295-302.

Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, **Mook S**, Van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. *Breast Cancer Res* 2008; 10: R93.

Eekhout I, **Mook S**, Rutgers EJT. MINDACT: 'Microarray in Node Negative Disease may Avoid ChemoTherapy': een unieke studie voor borstkankerpatiënten en onderzoeker. *Ned Tijdschr Oncol* 2008; 5: 225-8

Mook S, Cardoso F, Van 't Veer LJ. Personalized medicine by the use of microarray gene expression profiling. Bookchapter: Pharmacogenetics of Breast Cancer: Towards the Individualization of Therapy; Editor B. Leyland-Jones. Informa Healthcare; 1 edition (May 19, 2008).

Cardoso F, Van 't Veer L, Rutgers E, Loi S, **Mook S**, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. *J Clin Oncol* 2008; 26: 729-735.

Mook S, Van 't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. *Cancer Genomics Proteomics* 2007; 4: 147-155.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, **Mook S**, Decker N, Ravdin P, Therasse P, Rutgers E, Van 't Veer LJ, Piccart M. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. *Nat Clin Pract Oncol* 2006; 3: 540-551.

Mook S, Halkes Cj C, Bilecen S, Cabezas MC. In vivo regulation of plasma free fatty acids in insulin resistance. *Metabolism* 2004; 53: 1197-1201.

Esserman LJ, Shieh Y, Rutgers EJT, Knauer M, Retèl VP, **Mook S**, Glas AM, Moore DH, Linn S, van Leeuwen FE, Van 't Veer LJ. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. *JNCI, under review.*

Saghatchian M, **Mook S**, Pruneri G, Viale G, Glas A, Eekhout I, Cardoso F, Piccart M, Delaloge S, Van 't Veer L. Prognostic value of the 70-gene signature (MammaPrint) among breast cancer patients with 4-9 positive lymph nodes. *Manuscript in preparation.*

Bedard PL, **Mook S**, Knauer M, Durbecq V, Bernard-Marty C, Glas AM, Cardoso F, Van 't Veer LJ. The 70-gene profile (MammaPrint™) is an independent predictor of breast cancer specific survival for older women diagnosed with early breast cancer. *Manuscript in preparation.*